Thibaud Damy
YOU?
Author Swipe
View article: Prognostic impact of the number and Temporality of heart failure Hospitalisations: Analysis of a National healthcare database
Prognostic impact of the number and Temporality of heart failure Hospitalisations: Analysis of a National healthcare database Open
View article: The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network
The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network Open
Background Cardiac amyloidosis (CA) is a rare disease that can lead to poor quality of life, conduction disorders, arrhythmia, heart failure, and even death. Fortunately, specific treatments that can modify the natural history of the disea…
View article: Reduced Native T1 Values of Wrist Tissues in Transthyretin Cardiac Amyloidosis
Reduced Native T1 Values of Wrist Tissues in Transthyretin Cardiac Amyloidosis Open
Background/Objectives: Carpal tunnel syndrome (CTS) may signal extracardiac amyloid deposition years before transthyretin cardiac amyloidosis (ATTR-CA). This study investigated potential alterations of wrist tissue T1 values in ATTR-CA pat…
View article: Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association
Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association Open
This clinical consensus statement, developed by the Heart Failure Association of the European Society of Cardiology, offers a detailed review of the non-specific management of transthyretin amyloid cardiomyopathy (ATTR-CM). This progressiv…
View article: Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B Open
Patterns of associations between biomarkers and adverse outcomes support the importance of early treatment initiation and the potential for risk reduction in patients with ATTR-CM. Vutrisiran maintained stable or reduced levels of both bio…
View article: The impact of limited healthcare access among patients with light chain and transthyretin amyloidosis: real-world survey during COVID-19 lockdown period in France.
The impact of limited healthcare access among patients with light chain and transthyretin amyloidosis: real-world survey during COVID-19 lockdown period in France. Open
Patients with light chain amyloidosis reported having had a higher impact to their care management than transthyretin amyloidosis patients during the COVID19 pandemic containment periods.
View article: Vaccination in patients with heart failure in practice
Vaccination in patients with heart failure in practice Open
This narrative review underscores the pivotal role of vaccination in mitigating respiratory infections and associated acute decompensations in heart failure (HF) patients. It highlights the necessity for heightened awareness and proactive …
View article: Nonagenarian patients with ATTR cardiac amyloidosis: should they be treated with tafamidis?
Nonagenarian patients with ATTR cardiac amyloidosis: should they be treated with tafamidis? Open
View article: Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy and their caregivers: a post hoc analysis of an international survey
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy and their caregivers: a post hoc analysis of an international survey Open
Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition with debilitating symptoms. The self-reported burden of ATTR-CM on patients and their caregivers was previously evaluated in an international, multicent…
View article: Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage
Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage Open
Aims Tafamidis is an approved treatment for patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) based on the 30‐month Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). This post‐hoc analysis evaluated outcomes i…
View article: Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort
Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort Open
Background and Aims Outpatient cardiology follow-up is the cornerstone of heart failure (HF) management, requiring adaptation based on patient severity. However, risk stratification using administrative data is scarce, and the association …
View article: Olfactory and gustatory impairment in systemic cardiac amyloidosis: a prospective case-control study
Olfactory and gustatory impairment in systemic cardiac amyloidosis: a prospective case-control study Open
This study comparing olfactory function of CA patients to chronic non-amyloidotic heart failure patients found that CA patients had significantly more olfactory impairments. Olfactory impairments could therefore be a new "red flag" that ma…
View article: Hospitalisation for acute heart failure and in-hospital mortality before, during, and after the COVID-19 pandemic in France: A Nationwide cohort study from 2013 to 2024
Hospitalisation for acute heart failure and in-hospital mortality before, during, and after the COVID-19 pandemic in France: A Nationwide cohort study from 2013 to 2024 Open
Introduction Healthcare systems were reorganised in 2020 to manage the COVID-19 pandemic. Despite their urgent status, hospital admissions for acute heart failure (AHF) were reported to decline from 9% to 66% worldwide between 2020 and 202…
View article: Kidney Outcomes in Patients With Hereditary Transthyretin Amyloid Nephropathy Treated With Transthyretin Stabilizers And Gene-Silencer Therapies
Kidney Outcomes in Patients With Hereditary Transthyretin Amyloid Nephropathy Treated With Transthyretin Stabilizers And Gene-Silencer Therapies Open
Our study highlights the underrecognized risk of chronic kidney disease (CKD) and end-stage kidney disease in ATTRv and suggests that siRNA could be a promising therapeutic option for the stabilization of kidney function.
View article: Management of Rhythm and Conduction Disorders in Cardiac Amyloidosis
Management of Rhythm and Conduction Disorders in Cardiac Amyloidosis Open
View article: Amyloidogenic immunoglobulin light chains disturb contractile function and calcium transients in a human cardiac spheroid model of light chain (AL) amyloidosis
Amyloidogenic immunoglobulin light chains disturb contractile function and calcium transients in a human cardiac spheroid model of light chain (AL) amyloidosis Open
Light chain (AL) amyloidosis is a serious systemic disease caused by the deposition of free misfolded immunoglobulin light chains (LCs) in the form of amyloid fibrils within tissues. Cardiac involvement determines prognosis and mortality. …
View article: Corrigendum to “The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy” [International Journal of Cardiology Volume 417, 15 December 2024, 132542]
Corrigendum to “The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy” [International Journal of Cardiology Volume 417, 15 December 2024, 132542] Open
View article: Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies
Improving genetic testing pathways for transthyretin amyloidosis in France: challenges and strategies Open
Transthyretin amyloidosis (ATTR) is a severe and rare disease characterized by the progressive deposition of misfolded transthyretin proteins, causing irreversible organ damage. Transthyretin amyloidosis can present as a hereditary ATTR or…
View article: A series of cases of transthyretin amyloid cardiomyopathy with negative bone scintigraphy but a confirmed positive endomyocardial biopsy
A series of cases of transthyretin amyloid cardiomyopathy with negative bone scintigraphy but a confirmed positive endomyocardial biopsy Open
View article: Frailty in heart failure according to the presence or absence of wild‐type transthyretin cardiac amyloidosis
Frailty in heart failure according to the presence or absence of wild‐type transthyretin cardiac amyloidosis Open
Aims Wild‐type transthyretin cardiac amyloidosis (ATTRwt CA) is a common, underdiagnosed cause of heart failure (HF) in the elderly. Concurrent extracardiac amyloid infiltration might be responsible for a specific frailty phenotype. This s…
View article: The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy
The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy Open
Systematic genetic screening with a limited panel showed good performance, with diagnosis of Fabry disease (∼1 %) and hereditary TTR amyloidosis (∼3.5 %). Larger targeted panels were conclusive in 35.3 % of patients, of which 12 % had a ne…
View article: Diagnostic performance and relationships of structural parameters and strain components for the diagnosis of cardiac amyloidosis with MRI
Diagnostic performance and relationships of structural parameters and strain components for the diagnosis of cardiac amyloidosis with MRI Open
ECV outperforms FT-strain for the diagnosis of CA with cardiac MRI. The AB ratio of FT-GRS associated with myocardial T1 provides diagnostic performance similar to that achieved by ECV.
View article: First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia
First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia Open
Aims Cardiac amyloidosis (CA) is a potentially fatal multisystemic disease that remains significantly underdiagnosed, particularly in the Middle East. This study aims to evaluate the prevalence and clinical characteristics of CA in a high‐…
View article: Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Open
Among patients with ATTR-CM, treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals; HELIOS-B C…
View article: Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study
Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study Open
Background and Aims Based on retrospective studies, the 2022 European guidelines changed the definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF) by lowering the level of mean pulmonary artery pressure (mPAP) an…
View article: Phenotype and prognostic factors in geriatric and non‐geriatric patients with transthyretin cardiomyopathy
Phenotype and prognostic factors in geriatric and non‐geriatric patients with transthyretin cardiomyopathy Open
Aims Transthyretin cardiac amyloidosis (ATTR‐CM) may be an underestimated cause of heart failure among geriatric patients and represent a unique phenotype and prognostic profile. Methods and results This retrospective, observational, cohor…
View article: Long‐term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction
Long‐term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction Open
Aims Patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) present with diverse left ventricular ejection fraction (LVEF). This study assessed tafamidis efficacy by baseline LVEF in the phase 3 Tafamidis in Transthyretin Cardiomyopa…
View article: Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis
Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis Open
Background Cardiac amyloidosis (CA) is frequently found in older patients with aortic stenosis (AS). However, the prevalence of AS among patients with CA is unknown. The objective was to study the prevalence and prognostic impact of AS amo…
View article: Salt substitute recommendations for heart failure patients may influence guideline‐directed medical therapies titration
Salt substitute recommendations for heart failure patients may influence guideline‐directed medical therapies titration Open
Aims Reducing sodium intake is necessary for patients with chronic heart failure (CHF). Salt substitutes (saltSubs) have become increasingly popular as recommendations by healthcare professionals (HCPs) as well as options for patients and …
View article: Rationale and design of the PACIFIC-PRESERVED (PhenomApping, ClassIFication and Innovation for Cardiac dysfunction in patients with heart failure and PRESERVED left ventricular ejection fraction) study
Rationale and design of the PACIFIC-PRESERVED (PhenomApping, ClassIFication and Innovation for Cardiac dysfunction in patients with heart failure and PRESERVED left ventricular ejection fraction) study Open
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that is poorly defined, reflecting an incomplete understanding of its pathophysiology.